Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients

BMC Cancer

Takuto Hikichi¹  Hiroyuki Asama²  Ryoichiro Kobashi²  Tadayuki Takagi²  Hiromasa Ohira²  Mitsuru Sugimoto²  Hiroki Irie²  Mika Takasumi²  Yuki Sato²  Rei Suzuki²  Naoki Konno²  Minami Hashimoto³  Yoshinori Okubo³  Tsunetaka Kato³  Jun Nakamura³ 

[1] Department of Endoscopy, Fukushima Medical University Hospital, Fukushima, Japan;Department of Gastroenterology, School of Medicine, Fukushima Medical University, Fukushima, Japan;Department of Gastroenterology, School of Medicine, Fukushima Medical University, Fukushima, Japan;Department of Endoscopy, Fukushima Medical University Hospital, Fukushima, Japan;

关键词: chemotherapy-induced peripheral neuropathy;    mirogabalin;    pregabalin;    pancreatic cancer;   

DOI  :  10.1186/s12885-021-09069-9

来源: Springer

【 摘 要 】

BackgroundThe prognosis of pancreatic cancer (PC) has been improved by new chemotherapy regimens (combination of 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin (FOLFIRINOX) or gemcitabine plus nab-paclitaxel (GnP)). Unfortunately, chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse event of these two regimens. The efficacy of pregabalin for CIPN has been reported in previous studies. However, the efficacy of mirogabalin for CIPN remains unknown. Thus, in this study, we aimed to clarify which drug (mirogabalin or pregabalin) was more valuable for improving CIPN.MethodsA total of 163 PC patients who underwent FOLFIRINOX or GnP between May 2014 and January 2021 were enrolled. Among them, 34 patients were diagnosed with CIPN. Thirteen patients were treated with mirogabalin (mirogabalin group), and twenty-one patients were treated with pregabalin (pregabalin group). Treatment efficacy was compared between the two groups.ResultsIn both the mirogabalin group and the pregabalin group, the grade of patients with CIPN at 2, 4, and 6 weeks after the initiation of treatment showed significant improvement compared to the pretreatment grade. Notably, the rate of CIPN improvement was higher in the mirogabalin group than in the pregabalin group (2 weeks: 84.6% (11/13) vs 33.3% (7/21), P value = 0.005; 4 weeks, 6 weeks: 92.3% (12/13) vs 33.3% (7/21), P value = 0.001).ConclusionsAlthough both mirogabalin and pregabalin were effective at improving CIPN, mirogabalin might be a suitable first choice for CIPN in PC patients.Trial registrationNot applicable

【 授权许可】

CC BY